文献速递其他结缔组织病

边际结构模型显示环磷酰胺治疗严重幼年皮肌炎的疗效与安全性

Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling.
PubMed 文献 · Arthritis Rheumatol · 2018-03-25

研究分析幼年皮肌炎队列与生物标志物研究中56例接受环磷酰胺治疗的患者,未调整分析显示6、12、24个月时皮肤、整体和肌肉疾病均有改善,边际结构模型显示开始约6个月环磷酰胺疗程超过12个月的患者整体和皮肤疾病低于从未或尚未治疗者,结论认为环磷酰胺有效且无短期副作用,需进一步研究长期副作用。

要点

  • 56例接受环磷酰胺治疗的幼年皮肌炎患者,未调整分析显示6、12、24个月时皮肤、整体和肌肉疾病均较治疗开始时改善。
  • 边际结构模型显示,开始约6个月环磷酰胺疗程超过12个月的患者较从未或尚未治疗者整体疾病和皮肤疾病降低。
  • 治疗患者中改良皮肤疾病活动度评分低1.19单位(P=0.0085),医师整体评估低0.66单位(P=0.027)。

核心结论

  • 研究结果表明环磷酰胺有效且无短期副作用,皮肤、整体和肌肉疾病均有改善。
  • 需进一步研究评估长期副作用。

研究设计与样本

  • 分析幼年皮肌炎队列与生物标志物研究招募患者的皮肤、整体和肌肉疾病临床数据。
  • 采用未调整分析描述环磷酰胺治疗后的临床改善。
  • 采用边际结构模型模拟治疗疗效并调整适应证混杂。

主要发现

  • 与环磷酰胺治疗开始时相比,56例接受治疗患者在6、12、24个月时皮肤疾病(P=1.3×10-10)、整体疾病(P=2.4×10-8)和肌肉疾病(P=8.0×10-10)均有降低。
  • 有限证据提示接受环磷酰胺治疗患者糖皮质激素剂量降低(P=0.047)。
  • 边际结构模型分析显示,开始约6个月环磷酰胺疗程超过12个月的患者较从未或尚未接受环磷酰胺治疗者整体疾病和皮肤疾病降低。
  • 治疗患者中改良皮肤疾病活动度评分低1.19单位(P=0.0085),医师整体评估低0.66单位(P=0.027)。
  • 3例患者在停用环磷酰胺1年内报告轻微不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究评估长期副作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In patients with severe or refractory juvenile dermatomyositis (DM), second-line treatments may be required. Cyclophosphamide (CYC) is used to treat some connective tissue diseases, but evidence of its efficacy in juvenile DM is limited. This study was undertaken to describe clinical improvement in juvenile DM patients treated with CYC and model the efficacy of CYC treatment compared to no CYC treatment. METHODS: Clinical data on skin, global, and muscle disease for patients recruited to the Juvenile DM Cohort and Biomarker Study were analyzed. Clinical improvement following CYC treatment was described using unadjusted analysis. Marginal structural models (MSMs) were used to model treatment efficacy and adjust for confounding by indication. RESULTS: Compared to the start of CYC treatment, there were reductions at 6, 12, and 24 months in skin disease (P = 1.3 × 10-10 ), global disease (P = 2.4 × 10-8 ), and muscle disease (P = 8.0 × 10-10 ) for 56 patients treated with CYC in unadjusted analysis. Limited evidence suggested a reduction in glucocorticoid dose (P = 0.047) in patients treated with CYC. MSM analysis showed reduced global disease and skin disease in patients who started an ~6-month course of CYC treatment >12 months ago compared to patients never or not yet treated with CYC. In the treated patients, the modified skin Disease Activity Score for juvenile DM was 1.19 units lower (P = 0.0085) and the physician's global assessment was 0.66 units lower (P = 0.027). Minor adverse events were reported in 3 patients within 1 year of stopping CYC. CONCLUSION: Our findings indicate that CYC is efficacious with no short-term side effects. Improvements in skin, global, and muscle disease were observed. Further studies are required to evaluate longer-term side effects.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Deakin CT, Campanilho-Marques R, Simou S, et al. Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling. Arthritis Rheumatol. 2018. PMID: 29342499. doi:10.1002/art.40418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。